Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
46-60 of 4385 results
Ethypharm agrees to acquire UK-based Martindale Pharma
Ethypharm has agreed to acquire Martindale Pharma, a UK-based specialty pharmaceutical firm offering essential medicines to more than 50 countries across the world.
Drug Research > Drug Discovery & Development > News
Takeda, Ovid to co-develop rare pediatric epilepsy candidate TAK-935
Takeda Pharmaceutical said its rare pediatric epilepsy candidate TAK-935 will be co-developed through a partnership with Ovid Therapeutics.
Drug Research > Drug Discovery & Development > News
Horizon Discovery broadens gene editing capabilities
Horizon Discovery Group has expanded its gene editing capabilities through the amendment of a pre-existing license with ERS Genomics to include the full commercial rights for the use of CRISPR edited cell lines for the Good Manufacturing Practice (GMP) manufacturing of biotherapeutics.
Drug Research > Drug Discovery & Development > News
Malin buys 33% interest in UK's Wren Therapeutics
By PBR Staff Writer
Irish life sciences firm Malin has acquired a 33% stake in UK biopharmaceutical company, Wren Therapeutics.
Drug Research > Drug Discovery & Development > News
Aptevo Therapeutics receives $20m payment from Emergent BioSolutions
Aptevo Therapeutics has received a $20m cash payment from Emergent BioSolutions pursuant to a promissory note granted as a result of the spin-off of Aptevo from Emergent, effective August 1, 2016.
Drug Research > Drug Discovery & Development > News
Nivalis Therapeutics unveils corporate restructuring
Nivalis Therapeutics, a clinical stage pharmaceutical firm engaged in the development of new solutions for people with cystic fibrosis (CF), announced that its board of directors has approved a restructuring plan as part of its initiative to evaluate strategic alternatives focused on maximizing stockholder value from its clinical assets and cash resources.
Drug Research > Drug Discovery & Development > News
Clinical-stage biopharmaceutical firm OncoImmune raises $15m funding
OncoImmune, a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel immunotherapies for cancer, inflammation and autoimmune diseases, has secured $15m in Series A round of fundraising led by 3E Bioventures Capital.
Drug Research > Drug Discovery & Development > News
Merck expands oncology portfolio with four Vertex cancer programs
By PBR Staff Writer
Merck has agreed to license four oncology research and development (R&D) programs from Vertex Pharmaceuticals.
Drug Research > Drug Discovery & Development > News
Zebra Biologics to partner with AbbVie on new antibody therapeutics discovery
Pre-clinical stage biotechnology firm Zebra Biologics has partnered with AbbVie to discover agonist antibody therapeutics for inflammatory diseases.
Drug Research > Drug Discovery & Development > News
Silence Therapeutics acquires minority stake in Arrowhead Pharmaceuticals
Silence Therapeutics has made a $9.6m equity investment in Arrowhead Pharmaceuticals.
Drug Research > Drug Discovery & Development > News
Mast Therapeutics and Savara sign merger deal
Mast Therapeutics and Savara have entered into a definitive merger agreement, under which the stockholders of Savara would become the majority owners of Mast, and the operations of Mast and Savara would be combined.
Drug Research > Drug Discovery & Development > News
Takeda, PvP Biologics partner to develop novel therapeutic for celiac disease
Takeda Pharmaceutical and PvP Biologics have partnered to develop KumaMax, a novel enzyme designed to break down the immune-reactive parts of gluten in the stomach.
Drug Research > Drug Discovery & Development > News
Clinical stage biopharmaceutical firm Microbion raises $25m in funding
Quark Venture and GF Securities have invested $25m in Microbion to advance a new class of drugs that combat antibiotic-resistant infections.
Drug Research > Drug Discovery & Development > News
Scientists identify how cancer cells can shrug off physical constraints on growth and spread
Scientists have revealed how cancer cells are able to break free of the physical restraints imposed by their surroundings in order to grow and spread around the body.
Drug Research > Drug Discovery & Development > News
APT Therapeutics partners with AstraZeneca for human apyrase therapy
APT Therapeutics has signed a research collaboration, option and asset purchase agreement with AstraZeneca.
Drug Research > Drug Discovery & Development > News
46-60 of 4385 results